<DOC>
	<DOCNO>NCT00039039</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Drugs paclitaxel may make tumor cell sensitive radiation therapy . It yet know combination chemotherapy follow radiation therapy effective without paclitaxel treat unresectable stage III non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy follow radiation therapy without paclitaxel treat patient unresectable stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Radiation Therapy With Without Paclitaxel Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival rate patient unresectable stage III non-small cell lung cancer treat paclitaxel carboplatin cisplatin follow radiotherapy without concurrent paclitaxel . - Compare 1-year survival rate mean survival time patient treat regimen . - Compare objective response rate local control patient treat regimen . - Compare tolerability regimens patient . - Compare safety profile toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . All patient receive paclitaxel IV 3 hour follow carboplatin IV 30 minute cisplatin IV day 1 . Treatment repeat every 21 day 2 course . Patients proceed randomize treatment . - Arm I : Patients receive paclitaxel IV 1 hour day 1 radiotherapy day 1-5 week 6 week . - Arm II : Patients receive radiotherapy 5 day week 7 week . Patients follow every 3 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 300 patient ( 150 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III nonsmall cell lung cancer ( NSCLC ) Locoregionally advance unresectable disease Previously untreated Measurable disease No involvement supraclavicular lymph nod No cytologically positive pleural pericardial effusion No invasion wall esophagus cardiac ventricle No bone marrow involvement No distant metastases PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 01 Life expectancy : At least 12 week Hematopoietic : WBC great 4,000/mm^3 Absolute neutrophil count great 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le upper limit normal ( ULN ) AST ALT less 2.5 time ULN Alkaline phosphatase less 5 time ULN No hepatic abnormality Renal : Creatinine le ULN Cardiovascular : No myocardial infarction within past 6 month No cardiac insufficiency No uncontrolled arrhythmia Pulmonary : FEV1 great 1 L DLCO least 30 % predict No pneumonia No nondiseaserelated pulmonary complication Other : No 10 % total weight loss past 6 month No disease would preclude study No peripheral neuropathy grade 3 great No prior concurrent malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix No familial , geographic , psychological condition would preclude study Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy Endocrine therapy : No concurrent endocrine therapy Radiotherapy : No prior radiotherapy NSCLC Surgery : See Disease Characteristics No prior complete resection tumor Prior radical surgical resection allow local recurrence disease No concurrent major surgery Other : No concurrent anticancer therapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>